A study led by researchers at the University of Colorado Boulder, published in the journal Exploration of Medicine, is among the first to assess how cannabis bought over the counter at dispensaries—rather than government-supplied or synthetic varieties—impacts cancer symptoms or chemotherapy side effects.
In a first-in-human clinical trial for patients with relapsed multiple myeloma, led by researchers at Indiana University Melvin and Bren Simon Comprehensive Cancer Center, patients treated with higher doses of the immunotherapy called REGN5459 resulted in a 90.5% overall response rate.
While trying to understand what initiates breast cells to become cancerous, researchers at the Vera Bradley Foundation Center for Breast Cancer Research at Indiana University Melvin and Bren Simon Comprehensive Cancer Center have identified a new target for breast cancer treatment.
Moderna, Inc. and Merck announced April 16 the first presentation of detailed results from the phase IIb KEYNOTE-942/mRNA-4157-P201 trial evaluating mRNA-4157 (V940), an investigational individualized neoantigen therapy, in combination with KEYTRUDA, Merck’s anti-PD-1 therapy, in patients with resected high-risk melanoma (stage III/IV).
Data from a national clinical trial shows that a striking 89% of patients with desmoplastic melanoma responded to Keytruda (pembrolizumab) alone, suggesting that many patients could avoid the risk for toxicity from combination therapies and achieve cancer control with this approach to treatment.
Vitamin D deficiency could be the reason African American men experience more aggressive prostate cancer at a younger age compared with European American men, research from Cedars-Sinai Cancer suggests. The multi-institutional study, published in Cancer Research Communications, a journal of the American Association for Cancer Research, could pave the way for revised nutritional guidelines.
The FIGHT-207 trial, led by Jordi Rodon, associate professor of Investigational Cancer Therapeutics at MD Anderson Cancer Center, demonstrated promising early signs of clinical benefit and revealed potential mechanisms of primary and secondary resistance following treatment with the selective FGFR inhibitor pemigatinib in patients with advanced FGFR-altered solid tumors.
Two trials led by Timothy A. Yap, associate professor of Investigational Cancer Therapeutics at MD Anderson Cancer Center, showed encouraging results for treating solid tumors with DNA damage response alterations using a combination of PARP and ATR inhibitors. Notably, anti-tumor activity was seen in patients with tumors that had previously shown resistance to PARP inhibitors or platinum-based therapies.
The first-in-class YAP/TEAD inhibitor VT3989 was well tolerated with durable antitumor responses in patients with advanced malignant mesothelioma and other tumors with NF2 mutations, according to results of a phase I trial led by researchers at MD Anderson Cancer Center. The first-in-human study was presented today at the 2023 American Association for Cancer Research annual meeting.
The CD70-targeting allogeneic CAR T-cell therapy, ALLO-316, demonstrated encouraging response rates and disease control rates in patients with metastatic clear cell renal cell carcinoma, according to results of a phase I trial led by researchers at MD Anderson Cancer Center and presented at the American Association for Cancer Research annual meeting.
